Related Experiment Video

Updated: Jun 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During

Yinong Young-Xu1,2, Caroline Korves1,3, Gabrielle Zwain1,3

  • 1US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, Illinois, USA.

Open Forum Infectious Diseases
|December 28, 2023
PubMed

Insights

Sotrovimab significantly reduced COVID-19 hospitalization and mortality risk in high-risk veterans during Omicron BA.1 and BA.2 waves. This real-world study confirms sotrovimab

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacology
  • Real-World Evidence

Background:

  • The clinical effectiveness of sotrovimab for COVID-19 treatment, especially post-Omicron emergence, requires further investigation.
  • High-risk populations need effective interventions against severe COVID-19 outcomes.

Purpose of the Study:

  • To evaluate the real-world effectiveness of sotrovimab in preventing COVID-19-related hospitalization or mortality.
  • To assess sotrovimab's efficacy in high-risk veterans during the Omicron variant's dominance.

Main Methods:

  • Target trial emulation design using US Department of Veterans Affairs data.
  • Inclusion of veterans diagnosed with COVID-19 between December 2021 and April 2022.
  • Comparison of sotrovimab-treated patients (n=2816) with untreated controls (n=11,250) using Cox proportional hazards modeling.

Main Results:

  • Sotrovimab recipients were predominantly older (90% ≥50 years) and vaccinated.
  • During BA.1 dominance, sotrovimab reduced 30-day hospitalization/mortality risk by 70% (HR, 0.30).
  • During BA.2 dominance, sotrovimab reduced severe COVID-19 risk by 71% (HR, 0.29).

Conclusions:

  • Sotrovimab administration was associated with a reduced risk of 30-day COVID-19-related hospitalization or mortality in high-risk veterans.
  • Findings support sotrovimab's utility during Omicron BA.1 variant circulation.
  • Real-world data confirms sotrovimab's effectiveness in a predominantly vaccinated, high-risk cohort.
Abstract

Keywords:
COVID-19SARS-CoV-2monoclonal antibodiespreventionreal-world data

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...